Загрузка...
Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth
Aberrant Ras/Raf/MEK/ERK signaling is one of the most prevalent oncogenic alterations and confers survival advantage to tumor cells. Inhibition of this pathway can effectively suppress tumor cell growth. For example, sorafenib, a multi-kinase inhibitor targeting c-Raf and other oncogenic kinases, ha...
Сохранить в:
| Главные авторы: | , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2012
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3342476/ https://ncbi.nlm.nih.gov/pubmed/22286758 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2011.644 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|